SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia |
| |
| Affiliation: | 1. Gilead Sciences, Inc., Foster City, CA;2. Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC;3. University of Texas MD Anderson Cancer Center, Houston, TX;4. McMaster University, Hamilton, ON, Canada;5. H. Lee Moffitt Cancer Center, Tampa, FL;1. Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO;2. Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO;3. Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, University of Colorado School of Public Health, CO;4. Department of Radiology, University of Colorado School of Medicine, Aurora, CO;1. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland;2. Hematooncology Department, Copernicus Memorial Hospital, Lodz, Lodz, Poland;3. Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz Poland;4. School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland;5. Department of Hematology, Jagiellonian University Hospital, Krakow, Ploland;6. Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland;7. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland;8. Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland;9. Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;10. Department of Hematology, Wroclaw Medical University, Wroclaw, Wroclaw, Poland;11. Department of Hematology, Nicolaus Copernicus Specialist Municipal Hospital, Torun, Poland;12. Hematology Department, Rydygier Memorial Hospital, Krakow, Ploland;13. Department of Internal Diseases and Hematology, Military Institute of Medicine, Warsaw, Poland;14. Department of Hematology, Teaching Hospital No 1, Rzeszow, Poland;15. Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland;16. Department of Hematology and Cancer Prevention, Chorzow, Poland;17. Hematology Department, Jan Biziel University Hospital No. 2, Bydgoszcz, Poland;1. Department of Hematology, Shanghai Fourth People''s Hospital, School of Medicine, Tongji University, Shanghai, China;2. Department of Hematology, Changzheng Hospital, Shanghai, China;3. The First Hospital of Jilin University, Jilin, China;4. Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian, China;5. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China;6. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Clinical Research Center for Cancer, Tianjin, China;7. The First Affiliated Hospital of Soochow University, Suzhou, China;8. The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanzing, China;9. The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, China;10. Peking University First Hospital, Beijing, China;11. Department of Hematology, Zhongda Hospital Southeast University, Nanzing ,, China;12. Department of Hematology, West China Hospital Sichuan University, Chengdu, China;13. Janssen Research & Development, LLC, Spring House, Lower Gwynedd Township, PA,;14. Janssen Research & Development, LLC, Beijing, China;15. Janssen Research & Development, LLC, Shanghai, China;16. Peking University People''s Hospital, National Clinical Research Center for Hematologic Disease, Beijing, China;17. Collaborative Innovation Center of Hematology, Soochow, China;1. Helen Diller Family Comprehensive Cancer Center, San Francisco Medical Center, University of California, 18425 4th Street, San Francisco, CA, 94158, US;2. Janssen Research and Development, 920 US-202, Raritan, NJ, 08869, US;3. Legend Biotech, 10 Knightsbridge Road, Piscataway, NJ, 08554, US;4. Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, US;1. University of Arizona, Tucson, AZ;2. MD Anderson Cancer Center, Houston, TX;3. Department of Medicine, University of Arizona, Tucson, AZ;4. Department of Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ;5. Medical University of South Carolina, Charleston, SC |
| |
| Abstract: | Acute myeloid leukemia (AML) is an aggressive disease predominantly affecting the elderly population. Although, up to 65% of patients with AML achieve a complete remission with standard induction chemotherapy, the majority of patients will relapse and succumb to the disease. Although maintenance therapy is a component of standard management for various hematological malignancies, such as acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL) or multiple myeloma, past studies investigating the role of maintenance therapy in AML were unable to demonstrate an advantage in overall survival, and therefore, it has not been an established practice in the treatment of AML. For patients, who are not candidates for stem cell transplant, effective AML maintenance therapies are needed in order to reduce the risk of relapse. Over the past decades, many investigators have examined the role of various maintenance strategies in AML; with the intention to prolong remission and overall survival. This review will provide an overview of prior and ongoing approaches and strategies to maintenance therapy for AML. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
